Skip to main content
. 2011 Oct;164(4):1207–1229. doi: 10.1111/j.1476-5381.2010.01163.x

Table 2.

Magnesium and cyclosporin A evaluation in rodent TBI models

Drug TBI model Route of administration Time window Repeated administration Outcome measure Time for outcome
Magnesium lFPI16,1314,16,22 i.v.17,911,1316,18,19,22 Pre-injury3,22 Yes8,18 Cognition1,2,11,14,16,18,19,22 ≤7 days1,6,810,12,13,17,18,20
I/A711,15,17,1920 i.p.17,20,21 ≤1 h1,2,47,921 No17,917,1922 Motor/ 7–28 days25,11,14,19,21,22
CHI12 s.c.12 1–6 h8 Sensorymotor24,612,14,18,19,21 >28 days15,16
Bifrontal contusion18 i.m.8,10 >6 h8 Oedema2,17,20
CCI23,24,27,28 Lesion vol/cell death5,6,13,16,19,22
Rat122 Complex11,16
Mouse
Cyclosporin lFPI25,26,28 i.v.25,27 Pre-injury23,25 Yes2326,28* Cognition25,26 ≤7 days23,24,27,28
CCI23,24,27,28 i.p.23,26,28 ≤1 h23,24,26,27 No27 Motor/Sensorymotor25,26 7–28 days25,26
Rat2528 s.c.24 1–6 h28 >28 days
Mouse23,24 i.m. >6 h28 Oedema27
Lesion vol/cell death23,24,28
Complex

References to Table 2:

Overview of preclinical studies evaluating Mg2+ or cyclosporin A in rodent models of TBI.

*

Prolonged, >1 h infusion, included in the Repeated administration column.

CCI, controlled cortical contusion injury; CHI, closed head injury; i.m., intramuscular; i.p., intraperitoneal; i.v., intravenous; I/A, impact-acceleration; lFPI, lateral fluid percussion injury; s.c., subcutaneous; TBI, traumatic brain injury.